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Abstract
Background: Pelvic recurrences of cervical cancer after primary surgical treatment can be potentially cured with
radical hysterectomy or chemoradiation therapy. Combined radio-chemotherapy is believed to improve results
compared to other option. Currently, RapidArc radiotherapy is considered an excellent technological advance that
shows great potential for producing highly conformal doses to treatment volumes.
Case presentation: We present a case of a 67-year-old woman with history of early cervical cancer initially treated
by radical laparoscopic hysterectomy. More than 5 years later, the patient presented with a central pelvic vaginal
cuff recurrence that is histologically confirmed. Salvage radiotherapy using RapidArc with concurrent cisplatin-based
chemotherapy was indicated. A high dose of 70 Gy was delivered to the gross recurrent disease with simultaneous
integrated boost (SIB) to the subclinical disease and good sparing of organs at risk especially the rectum and
sigmoid.
Conclusions: This case clearly demonstrates a large benefit for salvage RapidArc radiotherapy to central pelvic
recurrences of gynecological cancers with an excellent rate of local control and less rate of toxicity.
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Background
Women with early-stage cervical cancer can be potentially
cured with radical hysterectomy or chemoradiation therapy
[1]. In Morocco, most patients present first at gynecologic
clinics and, as a result, the majority of patients of early stage
become subjected to radical hysterectomy and lymphade-
nectomy. Unfortunately, up to 17 % of women develop
either local and/or distant disease recurrence usually within
the first 2 years of completing the treatment [2, 3].
Local recurrence of cervical cancer after primary surgical
therapy is still problematic. It commonly occurs locally as
central pelvic recurrences due to the extent of spread into
contiguous tissues [4]. Treatment directed to the site of
recurrence can be performed with curative intent. Options
include radiation therapy (RT) or pelvic exenteration, both
resulting in suboptimal rates of local tumor control and
rates of survival [5, 6]. Recently, RapidArc radiotherapy is
considered an important technological advance that shows
great potential for producing highly conformal doses to
treatment volumes while sparing organs at risk (OARs).
We report an excellent complete response case of a
centrally recurrent squamous cell cervical cancer of the
vaginal cuff after radical laparoscopic hysterectomy, suc-
cessfully managed by salvage RapidArc radiotherapy and
concurrent cisplatin-based chemotherapy.
Case presentation
A 67-year-old female underwent a radical laparoscopic
hysterectomy, with adnexectomy and bilateral pelvic
lymphadenectomy for a FIGO stage IB1 squamous cell
cervical cancer in January 2010. Final pathology report
showed a 9-mm squamous cell carcinoma with deep
stromal invasion, positive resection margins, and one
metastatic lymph node, without vascular embolism or
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parametrium invasion. Based on pathologic risk factors,
adjuvant radiation therapy with radiosensitizing cisplatin
was suggested. Unfortunately, the patient was not com-
pliant, she was lost to follow-up and the adjuvant treat-
ment was never delivered.
In September 2014, the patient presented to our depart-
ment with abnormal vaginal bleeding and pelvic pain. On
pelvic examination, a tumor of an approximately 4 cm
gross circumferential at the vaginal cuff was palpated with
left parametrial involvement. A pelvis magnetic resonance
imaging (MRI) showed a central pelvic recurrence of the
vaginal cuff, as a left hemi circumferential tumor, measur-
ing 44 mm with intimate sigmoid contact and without
obstructive uropathy or pelvic wall involvement (Fig. 1). A
biopsy of the lesion demonstrated infiltrate and moder-
ately differentiated squamous cell carcinoma of the vaginal
cuff. Additional work up including CT scan of the chest
and abdomen does not found distant metastasis.
The patient was treated with dual arc RapidArc radio-
therapy. The treatment plan was designed to deliver in one
process with simultaneous integrated boost (SIB) a dose of
70 Gy to the planning target volume (PTV) based on the
gross disease in a 2-Gy daily fraction, 5 days a week. At the
same time, the subclinical disease was planned to receive
54 Gy in a 1.5-Gy daily fraction (Fig. 2). Seven cycles of
concurrent radiosensitizing cisplatin was also delivered
without toxicity.
A subsequent clinical evolution was marked by the
disappearance of bleeding and the tumor mass. MRI scan
realized 6 months after completing treatment showed a
complete response (Fig. 3).
Discussion
After primary surgery for cervical cancer, subsequent
pelvic recurrence is effectively managed with external
beam radiotherapy and concurrent cisplatin-based chemo-
therapy due to the presentation of a centrally recurrent
cervical cancer of the vaginal cuff, as seen in 35–40 % of
cases [7]. Surgical management is an option therapy but it
imposes radical pelvic surgery in order to achieve surgical
resection with curative intent. However, in locally recur-
rent disease, radiation offers long-term pelvic control and
prolonged survival [8].
One recent retrospective study examining outcomes of
patients undergoing salvage radiotherapy alone for recur-
rent cervical cancer following radical hysterectomy found
that is an effective treatment for who recur at the vaginal
cuff with relatively little morbidity but it is less effective in
patients where recurrence lies outside the central pelvis
[9]. Generally, it is accepted that the increasing dose to
the target volume in external beam radiotherapy will lead
to increased local control. Intensity-modulated radiother-
apy (IMRT) is seen as the way to achieve this. It facilitates
the delivery of differential doses of radiation to a specified
target volume and the escalating of dose prescription.
Early experience found that IMRT were able to achieve
excellent coverage of target volumes, and there was very
Fig. 1 a–c A pelvis MRI showed a centrally pelvic recurrence of the
vaginal cuff. Axial (a) and sagittal (b) T2W images show intermediate
left hemi circumferential signal intensity. Axial (c) T1 Gado image
shows hyperintense mass in the left cervix
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little acute gastrointestinal toxicity as compared with con-
ventional external beam radiotherapy techniques [10].
RapidArc radiotherapy is an excellent option used to
salvage our patient with a central pelvic vaginal cuff
recurrent lesion which seems to obtain better dosimetric
results compared to IMRT, with fewer monitor units,
and a significant decrease in treatment time [11]. Pelvic
radiation can lead to urinary symptoms and bowel
changes. However, RapidArc might reduce acute rectal
and bladder toxicity compared with conventional tech-
niques [12]. Concurrent cisplatin-based chemoradiother-
apy has also been used in the management of recurrent
cervical cancer. This approach has provided both better
local control and survival with acceptable toxicities in
women with locally recurrent cervical cancer in several
studies [13, 14].
Surveillance after primary curative therapy for cervical
cancer is uniformly recommended, although its effective-
ness is not well studied [15]. The concept of long-term
surveillance for patients treated with curative intent is
based on the premise that early detection of recurrence
may lead to treatments that have lower morbidity and
increase survival. Early detection of recurrence is aimed
at treating patients with potentially curative salvage ther-
apy. This is most likely in patients who have an isolated
central pelvic recurrence.
Conclusions
In summary, we have presented an excellent complete
response case of centrally recurrent cervical cancer of the
vaginal cuff following radical hysterectomy, which man-
aged by salvage RapidArc radiotherapy with concurrent
Fig. 2 a–f Axial, sagittal, and coronal images of computed tomography scan dosimetry showed our excellent conformity for dose distribution in
radiation therapy
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cisplatin-based chemotherapy. This case demonstrates a
large benefit for local dose escalation to the residual tumor
by the currently techniques with high rates of local control
and less rate of toxicity.
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Fig. 3 a–c Axial (a, c) and sagittal (b) MRI images showed a
complete response 6 months after completing the treatment
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